5:33 PM
 | 
Dec 21, 2012
 |  BC Extra  |  Clinical News

Actelion reports Phase II CDAD data

Actelion Ltd. (SIX:ATLN) said three doses of twice-daily oral cadazolid each produced "numerically similar" clinical cure rates, the primary endpoint, vs. oral...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >